

## Original article

# Percentage of patients with spondyloarthritis in patients referred because of chronic back pain and performance of classification criteria: experience from the Spondyloarthritis Caught Early (SPACE) cohort

Rosaline van den Berg<sup>1</sup>, Manouk de Hooge<sup>1</sup>, Floris van Gaalen<sup>1</sup>,  
Monique Reijnierse<sup>2</sup>, Tom Huizinga<sup>1</sup> and Désirée van der Heijde<sup>1</sup>

## Abstract

**Objectives.** The objectives of the study are to describe the Spondyloarthritis Caught Early (SPACE) cohort, present the performance of various SpA classification criteria and compare patients fulfilling the imaging arm with patients fulfilling the clinical arm of the Assessment of Spondyloarthritis international Society (ASAS) axSpA criteria on demographics, presence of SpA features and level of disease activity.

**Methods.** Patients with back pain ( $\geq 3$  months but  $\leq 2$  years, onset  $< 45$  years) visiting the rheumatology outpatient clinic of the Leiden University Medical Center were included in the SPACE cohort. Patients were classified according to the modified New York (mNY), ESSG, Amor and ASAS axSpA criteria. The sensitivity and specificity of criteria were tested against a rheumatologist's diagnosis.

**Results.** In total, 157 patients were included; 92 patients fulfilled any criteria, 11 fulfilled the mNY (sensitivity 16.9%, specificity 100%), 68 the ESSG (sensitivity 64.6%, specificity 71.7%), 48 the Amor (sensitivity 47.7%, specificity 81.5%) and 60 the ASAS axSpA criteria (sensitivity 84.6%, specificity 94.6%). Of those 60 patients, 30 fulfilled the imaging arm and 30 the clinical arm. Patients in the imaging arm are statistically significantly more often male, have a longer symptom duration and less often a positive family history for SpA than patients fulfilling the clinical arm. Patients in both arms are very similar regarding all other SpA features and level of disease activity.

**Conclusion.** The inclusion criteria of the SPACE cohort yield the same high numbers of SpA patients compared with referral strategies like inflammatory back pain, HLA-B27+ or sacroiliitis, yet are easier to apply. The ASAS axSpA criteria outperformed the other criteria; 38.2% fulfilled the ASAS axSpA criteria. Patients fulfilling the clinical arm of the ASAS axSpA reflect a group of patients similar to those fulfilling the imaging arm.

**Key words:** spondyloarthritis, classification criteria, referral, diagnosis.

## Introduction

SpA comprises a group of interrelated rheumatic diseases, including AS, PsA and arthritis associated with

IBD [1]. The diagnosis is challenging because of the lack of diagnostic criteria for (early) SpA.

Over the years, several criteria sets have been developed to classify patients with SpA. The modified New York (mNY) criteria are available to classify patients with AS [2], however, they are of limited use in early disease or other subtypes of SpA [3]. The ESSG and the Amor criteria are widely used to define the whole concept of SpA [4, 5]. More recently, the Assessment of Spondyloarthritis international Society (ASAS) developed criteria to classify

<sup>1</sup>Department of Rheumatology and <sup>2</sup>Department of Radiology, Leiden University Medical Center, Leiden, The Netherlands.

Submitted 30 October 2012; revised version accepted 18 March 2013.

Correspondence to: Désirée van der Heijde, Department of Rheumatology, Leiden University Medical Center, PO Box 9600, 2300 RC Leiden, The Netherlands. E-mail: mail@dvanderheijde.nl

patients with predominantly axial SpA (axSpA) and criteria to classify patients with predominantly peripheral SpA [6, 7]. It is possible to classify patients as having axSpA according to the imaging arm if they have sacroiliitis on radiographs and/or MRI plus at least one additional SpA feature, or according to the clinical arm based on HLA-B27 positivity in combination with at least two other SpA features [6]. Yet the question arose of whether patients fulfilling the clinical arm reflect a group of patients similar to those fulfilling the imaging arm.

The ASAS axSpA criteria should be applied in patients with back pain (almost daily for  $\geq 3$  months, onset  $< 45$  years) of unknown origin, which is considered to be the leading symptom of axSpA [8]. However, it is difficult to recognize axSpA in an early stage among the enormous number of patients with back pain, since the clinical presentation of axSpA is very heterogeneous and there is no single shared distinguishing feature [9]. Hence some have stated that not just chronic back pain, but specific inflammatory back pain (IBP) is typical of axSpA [10]. Therefore IBP is often proposed as one of the referral parameters [11, 12]. However, there is increasing evidence that not all patients with axSpA have IBP, and vice versa, which is also evident from the relatively low sensitivity and specificity of IBP criteria (e.g. 79.6% and 72.4%, respectively, for the ASAS IBP criteria) [3, 13–16].

The SpondyloArthritis Caught Early (SPACE) cohort in the Leiden University Medical Center (LUMC) in Leiden, the Netherlands, uses chronic back pain ( $\geq 3$  months but  $\leq 2$  years, onset  $< 45$  years) as the only inclusion criteria. These inclusion criteria are, to our knowledge, unique for an SpA cohort. Other early back pain cohorts like ESPAC (the Early SPondyloArthritis Clinic) and DESIR (DEvenir des Spondylarthropathies Indifférenciées Récentes) included only patients with IBP [17, 18].

The goal of this study is to give a description of the characteristics of the patients included in the SPACE cohort. The percentage of patients fulfilling at least one of the classification criteria sets for SpA is given. Second, the performance of the various classification criteria for SpA is tested. Furthermore, demographics, number of SpA features and level of disease activity in patients fulfilling the imaging arm and patients fulfilling the clinical arm of the ASAS axSpA criteria are compared.

## Patients and methods

### Patients

The SpondyloArthritis Caught Early (SPACE) cohort started in January 2009 and is an ongoing project. General practitioners as well as other specialists such as ophthalmologists and gastroenterologists were informed about the start of the SPACE cohort and about the inclusion criteria. Patients aged 16 years and older with chronic (almost daily) back pain for  $\geq 3$  months but  $\leq 2$  years with the onset before the age of 45 years referred to the rheumatology outpatient clinic of the LUMC were included after signing informed consent. The SPACE study protocol was approved by the local medical ethics committee of the

LUMC. Patients could not be included if other painful conditions not related to SpA could interfere with the evaluation of disease activity or if any reason was present that was likely to invalidate informed consent or limit the ability of the subject to comply with the protocol requirements.

### Assessments and visits

All patients underwent a diagnostic workup at baseline; descriptions of the performed diagnostic workup follow below. Thereafter only patients with definite or possible SpA were included for follow-up visits after 3, 12 and 24 months. Definite axSpA is defined as a patient fulfilling the ASAS axSpA criteria. Possible SpA is defined as the presence of at least one of the following specific SpA features [high likelihood ratio (LR+)] [6, 14]: HLA-B27 positivity, positive family history for SpA, sacroiliitis (MRI or radiographs), acute anterior uveitis or at least two of the following less-specific SpA features (lower LR+): IBP (ASAS definition [16]), (heel) enthesitis, peripheral arthritis, psoriasis, IBD, good response to NSAIDs or elevated levels of ESR or CRP, but not fulfilling any of the classification criteria. Annual visits after the first 2 years were scheduled for patients with definite axSpA (ASAS criteria). Unless otherwise specified, all measurements were performed by one of the researchers (R.v.d.B. or M.d.H.) during every visit.

### Physical examination

In total, 68 joints were examined for tenderness and 66 for swelling. Entheses were examined according to the Maastricht Ankylosing Spondylitis Enthesitis Score (MASES) index [19]. Spinal mobility was assessed by measuring chest expansion, occiput to wall distance, modified Schober test, cervical rotation, lateral spinal flexion and intermalleolar distance as described in the ASAS handbook [20]. The tragus-to-wall distance was derived from the OWD by adding 8 cm to the OWD score. By doing so, the value of zero in the OWD corresponds to a score of zero in the calculation of the BASMI [21]. Based on these measurements, the BASMI was calculated [21].

### Patient-reported questionnaires

Patients completed the BASDAI [22] and BASFI [23].

### Other parameters

Overall assessment of disease activity was done by the physician on an 11-point numerical rating scale (NRS), 0 representing inactive disease and 10 extremely active disease. The presence (past or current) of extra-spinal and extra-articular manifestations [acute anterior uveitis, urethritis, balanitis, cervicitis, IBD and psoriasis, enthesitis and a positive family history of SpA (AS, reactive arthritis, psoriasis, IBD, uveitis) all according to the definition of the ASAS criteria [6]] was recorded. Treatment with NSAIDs, DMARDs and biologic therapies was recorded. NSAID intake is recorded according to the ASAS recommendations [24]. A good response of back pain to a full dose of

NSAID was defined as not present anymore or much better [6]. Furthermore, the Ankylosing Spondylitis Disease Activity Score (ASDAS) was calculated [25]. More information about performed measurements during the visits can be found in the supplementary data, available at *Rheumatology* Online.

### Laboratory assessment

The laboratory assessment during each visit consisted of measurements of ESR (Westergren method in mm/1 h) and CRP (ELISA in mg/l). HLA-B27 was only typed at baseline.

### Imaging assessment

MR imaging was performed on a 1.5T (Philips Medical Systems, Best, Netherlands) T1-weighted turbo spin echo (T1TSE) (TR 550/TE 10) and short tau inversion recovery (STIR) (TR 2500/TE 60) sequences were acquired, coronal oblique of the SI joints (MRI-SI). The slice thickness was 4 mm. Radiographs of the pelvis (anterior-posterior view) were performed at baseline, after 1 and 2 years, and thereafter every second year.

SI joints, both on MRI and on radiograph, were independently scored by two trained readers (M.d.H. and R.v.d.B.). MRI-SIs were scored on the presence of bone marrow edema (BME) according to the ASAS/OMERACT definition [26], according to the Spondyloarthritis Research Consortium of Canada (SPARCC) score [27] and on the presence of capsulitis/enthesitis. All radiographs of the SI joints (X-SIs) were scored according to the modified mNY criteria [2]. In case the first two readers disagreed on an image [MRI (ASAS/OMERACT definition) or radiograph], a third trained reader (V.N.) served as adjudicator. If two of three readers scored positive, the image was marked positive. Moreover, all positive X-SIs were checked by a senior rheumatologist (D.v.d.H.) who gave a final judgement about the X-SI. All readers were blinded for clinical and laboratory data as well as the results of the other imaging modality.

### Diagnosing the patients

A rheumatologist experienced in the field of SpA diagnosed all patients as predominantly axSpA, both axSpA and peripheral SpA, or no SpA based on all collected information, including imaging and HLA-B27 status. For this analysis, patients with only axSpA were used. In the case of no SpA, the rheumatologists filled out another suitable diagnosis. Furthermore, the rheumatologist marked the level of confidence about the diagnosis, either SpA or no SpA, on an 11-point NRS from 0 (not confident at all) to 10 (very confident).

### Classification of patients

All patients were classified according to the Amor, ESSG, mNY and ASAS axSpA criteria [2, 4–6]. In addition, both the ESSG and AMOR criteria were modified by judging active sacroiliitis on MRI similarly to radiographic sacroiliitis.

### Data analysis

For the present analysis, only data of the baseline visit were used. First, it was investigated how many patients fulfilled at least one of the classification criteria sets for SpA, shown in Venn diagrams.

Next, the number of patients diagnosed as axSpA according to the rheumatologist was described. The diagnosis of the rheumatologist served as external standard to test the performance of the various classification criteria. The performance was determined by calculating sensitivity, specificity, positive likelihood ratio (LR+) and negative likelihood ratio (LR–). For further analyses, the ASAS axSpA criteria set was selected to differentiate between SpA and no-SpA patients. Characteristics of the patients were described using *t*-tests and  $\chi^2$  tests.

In a following step, the ASAS axSpA criteria were studied in more detail. Patients fulfilling the clinical arm and patients fulfilling the imaging arm were compared on demographics, the presence of SpA features and level of disease activity. Furthermore, within the imaging arm, patients with sacroiliitis on radiograph were compared with patients with sacroiliitis on MRI only, also by *t*-tests and  $\chi^2$  tests.

Missing values for the presence of SpA features were interpreted as being absent. All analyses were performed using SPSS version 17. *P*-values <0.05 were considered significant.

## Results


### Performance of classification criteria

In total, 157 patients were included in the SPACE cohort. The mean age at inclusion was 31.2 (s.d. 12.6) years, the mean symptom duration was 13.5 (s.d. 7.2) months and 33.1% were male. Of the 157 patients, 92 (58.6%) fulfilled any classification criteria set at baseline. Sixty (38.2%) patients fulfilled the ASAS axSpA criteria; this percentage has been similar over the years the SPACE cohort has been running (40.4% in 2009, 36.2% in 2010, 38.9% in 2011 and 34.1% in 2012). Thirty-nine of these 60 patients fulfilled at least one other criteria set as well. Sixty-eight (43.3%) patients fulfilled the ESSG criteria; 53/68 fulfilled at least one other criteria set as well. Forty-eight (30.6%) patients fulfilled the Amor criteria; the majority of the patients (45/48) also fulfilled another criteria set. Eleven (7.0%) patients fulfilled the mNY criteria; all fulfilled at least one other classification criteria as well. Nine patients fulfilled all four criteria sets, 15 patients fulfilled three criteria sets (14 the combination of ASAS axSpA, ESSG and Amor and 1 the combination of ASAS axSpA, Amor and mNY) and 38 patients fulfilled two criteria sets (16 both ASAS axSpA and ESSG, 7 both ASAS axSpA and Amor, 14 both ESSG and Amor and 1 both ASAS axSpA and mNY) (Fig. 1).

To calculate the performance of the various classification criteria, the diagnosis of the rheumatologist was used as external standard. The rheumatologist diagnosed 65 patients (41.4%) as axSpA and 92 patients as no SpA. The mean level of confidence about the diagnosis is

similar for patients fulfilling the ESSG, Amor and ASAS axSpA criteria (6.2–6.7 out of 10), but higher for patients fulfilling the mNY criteria (7.8 out of 10) (Table 1). The mNY criteria showed the lowest sensitivity (16.9%) but highest specificity (100%). The Amor criteria showed a sensitivity of 47.7%, which increased to 67.7% in the modified version, without a decrease in specificity (71.7%). The ESSG criteria showed a sensitivity of 64.6%, which increased to 75.4% in the modified version without a decrease in specificity (81.5%). The ASAS axSpA criteria outperformed all other classification criteria, including the modified Amor and modified ESSG criteria, in terms of sensitivity (84.6%), specificity (94.6%), LR+ (15.6) and LR– (0.16) (Table 1). For all further analyses we used the ASAS axSpA criteria for the definition if a patient fits into the category axSpA or no SpA. This criterion is exactly defined and reproducible for readers, while the diagnosis by the rheumatologist is not.

**Fig. 1** Venn diagram representing the overlap between the various classification criteria for axial SpA.



### Patient characteristics

The majority of the patients referred to the SPACE cohort were from the Leiden area; over the years, 17.0%, 7.3%, 10.2% and 17.7% of the referrals in 2009, 2010, 2011 and 2012, respectively, were from outside the Leiden area.

Thirty-three patients were not included for follow-up because of the lack of specific SpA features; 13 patients did not have any SpA features and the remaining 20 patients had only one less specific SpA feature (1 patient with peripheral arthritis only, 1 patient with heel enthesitis only, 6 patients with a good response to NSAIDs only, 12 patients with IBP only). Of the patients included for follow-up, 64 had possible SpA and the remaining 60 patients fulfilled the ASAS axSpA criteria.

Patients classified as axSpA according to the ASAS axSpA criteria were compared with the group of no-axSpA patients including possible SpA patients and patients excluded for follow-up, revealing some statistically significant differences. AxSpA patients are more frequently male ( $P=0.001$ ), more often have a positive family history for SpA ( $P=0.001$ ), IBP ( $P=0.001$ ), a good response to NSAIDs ( $P=0.004$ ) and sacroiliitis on radiograph ( $P<0.001$ ) and MRI ( $P<0.001$ ), and are more often HLA-B27 positive ( $P<0.001$ ) compared with no-axSpA patients. Furthermore, there was a trend that axSpA patients more often have uveitis ( $P=0.07$ ) and higher levels of ESR ( $P=0.08$ ) (Table 2).

### ASAS imaging arm vs clinical arm

The comparison of patients fulfilling the imaging arm with patients fulfilling the clinical arm revealed that patients in the imaging arm are more often male ( $P=0.02$ ), have a longer symptom duration ( $P=0.04$ ) and less often have a positive family history for SpA ( $P=0.001$ ) than patients fulfilling the clinical arm. However, patients fulfilling the clinical arm reflect a group of patients similar to those fulfilling the imaging arm with respect to the presence of other SpA features and level of disease activity (Table 3). Nevertheless, the mean level of confidence about the diagnosis axSpA in patients fulfilling the clinical arm of the ASAS axSpA criteria ( $4.9 \pm 1.5$ ) is lower in comparison to the level of confidence about the diagnosis in patients

**TABLE 1** Performance of various axSpA classification criteria with the diagnosis of the rheumatologist as external standard

AxSpA patients vs no-axSpA patients	axSpA patients ( $n=65$ ), $n$ positive (sensitivity)	No-axSpA patients ( $n=92$ ), $n$ negative (specificity)	LR+	LR–	Confidence about the diagnosis axSpA, mean (s.d.)
ASAS axSpA	55 (84.6)	87 (94.6)	15.6	0.16	6.4 (1.8)
mNY	11 (16.9)	92 (100)	15.6	0.99	7.8 (1.1)
ESSG	42 (64.6)	66 (71.7)	2.3	0.49	6.2 (1.7)
Amor	31 (47.7)	75 (81.5)	2.6	0.64	6.5 (1.7)
Modified ESSG (with MRI)	49 (75.4)	66 (71.7)	2.7	0.34	6.4 (1.7)
Modified Amor (with MRI)	44 (67.7)	75 (81.5)	3.7	0.40	6.7 (1.6)

Level of confidence about the diagnosis SpA on an 11-point NRS from 0 (not confident at all) to 10 (very confident).



**TABLE 2** Baseline characteristics of axSpA patients vs no-axSpA patients according to the ASAS axSpA criteria

	axSpA patients ( <i>n</i> = 60)	No-axSpA patients ( <i>n</i> = 97)	<i>P</i> -value (axSpA vs no-axSpA patients)
Age at inclusion, mean (s.d.), years	29.5 (8.7)	32.3 (14.4)	0.17
Male, <i>n</i> (%)	29 (48.3)	23 (23.7)	0.001
Duration of back pain, mean (s.d.), months	13.4 (7.7)	13.6 (6.9)	0.88
HLA-B27 positive, <i>n</i> (%)	47 (79.7)	6 (6.2)	<0.001
Positive family history of SpA, <i>n</i> (%)	31 (51.7)	25 (25.8)	0.001
IBP, <i>n</i> (%)	50 (83.3)	55 (56.7)	0.001
Psoriasis, <i>n</i> (%)	8 (13.3)	8 (8.2)	0.31
Dactylitis, <i>n</i> (%)	3 (5.0)	3 (3.1)	0.55
Enthesitis, <i>n</i> (%)	8 (13.3)	17 (17.5)	0.49
Uveitis, <i>n</i> (%)	9 (15.0)	6 (6.2)	0.07
IBD, <i>n</i> (%)	3 (5.0)	6 (6.2)	0.76
Preceding infection, <i>n</i> (%)	1 (1.7)	1 (1.0)	0.73
CRP, mean (s.d.), mg/l	8.4 (11.9)	5.8 (6.9)	0.12
ESR, mean (s.d.), mm/h	14.4 (16.7)	10.1 (10.6)	0.08
Alternating buttock pain, <i>n</i> (%)	16 (26.7)	17 (17.5)	0.17
Good response to NSAIDs, <i>n</i> (%)	29 (48.3)	25 (25.8)	0.004
Elevated CRP/ESR, <i>n</i> (%)	16 (26.7)	15 (15.5)	0.09
Asymmetric lower limb arthritis, <i>n</i> (%)	8 (13.3)	15 (15.5)	0.71
Sacroiliitis radiograph, <i>n</i> (%)	11 (18.3)	1 (1.1)	<0.001
Sacroiliitis MRI, <i>n</i> (%)	25 (41.7)	2 (2.1)	<0.001

Preceding infection can be balanitis, urethritis, cervicitis and/or acute diarrhoea.

fulfilling the imaging arm ( $7.7 \pm 0.8$ ). Within the imaging arm, patients with and without sacroiliitis on radiographs were compared. Remarkably, there was no difference in symptom duration (Table 3).

## Discussion

The SPACE cohort consists of patients with chronic back pain ( $\geq 3$  months, but  $\leq 2$  years, onset  $< 45$  years). The only available numbers about the prevalence of chronic back pain ( $\geq 3$  months duration) in the Netherlands stem from the mid-90s and show a prevalence of 20.8% [28]. The majority of these patients (90%) have non-specific back pain [29]. Hence Dutch rheumatologists in general, and likewise rheumatologists in our department, feared that outpatient clinics would be overloaded by patients with non-specific back pain by using the above-described criteria as the sole referral symptom, although we showed that this fear is unfounded in at least the setting of a tertiary hospital, since  $\sim 60\%$  of the patients in the SPACE cohort fulfil one or more axSpA classification criteria at baseline and 41.4% of patients are directly diagnosed as SpA by the rheumatologist. Moreover, in the light of these results, the value of the numbers about prevalence of chronic back pain from the mid-90s is questionable, thereby indicating that more up-to-date numbers are needed. Furthermore, this percentage of SpA is similar to the percentage of 41.8% found by a multicentre study using a referral strategy consisting of the presence of either IBP or HLA-B27 or sacroiliitis on imaging (MRI and/or radiograph) [11] and the 35.1% found in a study using IBP or a good response to NSAIDs as referral symptom [12]. Although the test result

for the presence of HLA-B27 is not difficult to interpret, it is challenging for referring physicians to interpret back pain as inflammatory or not and to detect sacroiliitis, as demonstrated by the low agreement between general practitioners and rheumatologists [11].

It could be argued that our observed prevalence of axSpA is influenced by referral bias; e.g. that due to increased awareness among referring physicians about the SPACE cohort over time, patients from areas other than the Leiden area are referred to the LUMC or that only patients with a high suspicion of axSpA are referred. However, the percentage of axSpA among all referred patients over the years was similar, and the percentage of referrals from outside the Leiden area was also similar over time. Moreover, 33 of the 157 patients (21.0%) included at baseline had none or only one less specific SpA feature. This indicates, but does not prove, that there is no referral bias, thereby suggesting that the observed prevalence of axSpA could be generalized to primary care. In addition, other studies should investigate the prevalence of SpA among patients with chronic back pain  $> 2$  years previously not recognized as SpA.

Around 80% of the axSpA patients in the SPACE cohort have IBP, thereby confirming that IBP is not present in all SpA patients [13]. Moreover, IBP is frequently (56.7%) present in no-SpA patients in the SPACE cohort, which is consistent with the 45.1% found in another study [11]. These results show that IBP is not a strong discriminating feature and that if IBP was used as an inclusion criterion instead of chronic back pain, 20% of the SpA patients would have been missed.

**TABLE 3** Characteristics of patients in the clinical arm compared with patients in the imaging arm of the ASAS axSpA criteria

	Imaging arm (n = 30)			Clinical arm (n = 30)	P-value (imaging arm vs clinical arm)
	mNY+ (n = 11)	mNY- (n = 19)	Total (n = 30)		
Age at inclusion, mean (s.d.), years	28.6 (9.6)	32.9 (8.7)	31.2 (9.0)	28.2 (8.4)	0.14
Male, n (%)	8 (72.7)	11 (57.9)	19 (63.3)	10 (33.3)	0.02
Duration of back pain, mean (s.d.), months	15.6 (8.5)	16.0 (6.9)	15.5 (7.6)	11.4 (7.3)	0.04
HLA-B27 positive, n (%)	6 (54.5)	11 (61.1)	17 (58.6)	30 (100)	<0.001
Positive family history of SpA, n (%)	4 (36.4)	5 (26.3)	9 (30.0)	22 (73.3)	0.001
IBP, n (%)	9 (81.8)	14 (73.7)	23 (76.7)	27 (90.0)	0.17
Psoriasis, n (%)	2 (18.2)	2 (10.5)	4 (13.3)	4 (13.3)	1
Dactylitis, n (%)	0 (0.0)	2 (10.5)	2 (6.7)	1 (3.3)	0.55
Enthesitis, n (%)	2 (18.2)	2 (10.5)	4 (13.3)	4 (13.3)	1
Uveitis, n (%)	1 (9.1)	1 (5.3)	2 (6.7)	7 (23.3)	0.07
IBD, n (%)	2 (18.2)	1 (5.3)	3 (10.0)	0 (0.0)	0.08
Preceding infection, n (%)	0 (0.0)	0 (0.0)	0 (0.0)	1 (3.3)	0.31
CRP, mean (s.d.), mg/l	6.9 (7.2)	7.6 (8.6)	7.3 (8.0)	15.6 (18.9)	0.58
ESR, mean (s.d.), mm/h	11.4 (13.9)	14.2 (14.8)	13.2 (14.3)	9.4 (14.9)	0.50
Alternating buttock pain, n (%)	6 (54.5)	5 (26.3)	11 (36.7)	5 (16.7)	0.08
Good response to NSAIDs, n (%)	6 (54.5)	10 (52.6)	16 (53.3)	13 (43.3)	0.44
Elevated CRP/ESR, n (%)	4 (36.4)	5 (26.3)	9 (30.0)	7 (23.3)	0.56
Asymmetric lower limb arthritis, n (%)	0 (0.0)	4 (21.1)	4 (13.3)	4 (13.3)	1
Sacroiliitis radiograph, n (%)	11 (100)	—	11 (36.7)	—	—
Sacroiliitis MRI, n (%)	6 (54.5) <sup>a</sup>	19 (100) <sup>a</sup>	25 (86.2)	—	—
BASDAI	3.7 ± 1.8	4.0 ± 2.5	3.9 ± 2.3	3.9 ± 1.9	0.97
ASDAS	2.4 ± 0.7	2.5 ± 0.9	2.4 ± 0.8	2.4 ± 0.9	0.94
BASFI	3.3 ± 1.9	2.4 ± 2.2	2.7 ± 2.1	2.3 ± 2.2	0.50
BASMI	1.9 ± 0.7	1.6 ± 0.5	1.7 ± 0.6	1.6 ± 0.8	0.51
NSAID use, n (%)	9 (81.8)	15 (78.9)	24 (80.0)	22 (73.3)	0.54
DMARD use, n (%)	1 (9.1)	1 (5.3)	2 (6.7)	1 (3.3)	0.55
Biologic use, n (%)	0 (0.0)	1 (5.3)	1 (3.3)	0 (0.0)	0.31
Confidence about the diagnosis axSpA, mean (s.d.)	7.8 (1.1)	7.5 (0.6)	7.7 (0.8)	4.9 (1.5)	<0.001

Preceding infection can be balanitis, urethritis, cervicitis and/or acute diarrhoea. Level of confidence about the diagnosis of SpA on an 11-point NRS from 0 (not confident at all) to 10 (very confident). <sup>a</sup>Statistically significant difference between patients fulfilling the mNY criteria and patients not fulfilling the mNY criteria within the total imaging arm.

Depending on the presence and type of SpA features, patients fulfil various classification criteria. The performance of the Amor, ESSG and ASAS axSpA criteria was better than the mNY criteria at the time of presentation of patients to rheumatologists. This can be explained by the fact that it takes several years before patients develop radiographic sacroiliitis [30]. Moreover, the ASAS axSpA criteria outperformed the Amor and ESSG criteria, even after adding active sacroiliitis (MRI) to the list of SpA features. These results are in contrast with the results found in a more established cohort [the Cochin Spondyloarthritis (COSPA) cohort] where the ASAS axSpA criteria (fulfilled by 90% of the patients) did not have additional value in comparison to the Amor (fulfilled by 96% of the patients) and ESSG criteria (fulfilled by 83% of the patients) [31]. A possible explanation for these contrasting results is that the longer the symptom duration, the more chance that (extra-articular) features develop. To fulfil the Amor criteria, a patient needs to

have at least 6 points representing three to four items. This is quite difficult to reach, especially for patients early in the disease, as in the SPACE cohort, reflected by the fact that only 31% of these patients fulfilled the Amor criteria. Patients in the COSPA cohort, however, had a mean symptom duration of 16 years (range 8–27 years) and therefore fulfil the Amor criteria more easily.

To fulfil the ESSG criteria, a patient needs to have either IBP or synovitis (asymmetric or predominantly in the lower limbs) and at least one additional feature. The focus of the SPACE cohort is towards axSpA and not peripheral SpA, and therefore the number of patients with peripheral complaints (synovitis) is low. Furthermore, IBP is only present in about 80% of the axSpA patients in the SPACE cohort. Therefore it is not possible for some patients to fulfil the ESSG criteria.

It could be argued that the good performance of the ASAS axSpA criteria might be biased by the fact that

patients are diagnosed by only one rheumatologist accustomed to work with the ASAS axSpA. However, this bias is unlikely when looking at the level of confidence about the diagnosis, which is similar for patients fulfilling the ESSG, Amor and ASAS axSpA criteria, and when looking at the small numbers of misclassifications by the ASAS axSpA criteria compared with the diagnoses yielded by the modified Berlin algorithm, which is a diagnostic tool [32]. The ASAS axSpA criteria yield 3.8–6.1% of wrongly diagnosed patients as SpA and 7.6–10.2% of missed diagnoses compared with the modified Berlin algorithm. It might even support the rationale to use the ASAS axSpA criteria as diagnostic criteria in this type of setting with referrals to rheumatologists based on chronic back pain starting before the age of 45.

Within the ASAS axSpA criteria, it was questioned whether patients fulfilling the clinical arm of the ASAS axSpA criteria reflect the same disease as patients fulfilling the imaging arm. We found that patients in the SPACE cohort fulfilling the clinical arm were remarkably similar to patients fulfilling the imaging arm with respect to the presence of most SpA features and level of disease activity. Another study (ABILITY I trial) found the same results [33]. However, the difference in level of confidence about the diagnosis indicates that the judgement by the rheumatologist is heavily weighted by positive imaging. Furthermore, within the imaging arm of the ASAS axSpA criteria, patients with sacroiliitis on radiographs have the same level of disease activity and symptom duration as patients with sacroiliitis on MRI only.

In conclusion, the inclusion criteria used for the SPACE cohort, almost daily chronic back pain of short duration ( $\leq 2$  years) starting before the age of 45 years (in accordance with the entry criteria for the ASAS axSpA criteria), yield the same high number of patients with SpA compared with other referral strategies such as IBP, HLA-B27+ or sacroiliitis, yet are easier to apply. Furthermore, the ASAS axSpA criteria outperformed the other classification criteria; almost 40% fulfilled the ASAS axSpA criteria. Patients fulfilling the clinical arm of the ASAS axSpA reflect a group of patients similar to those fulfilling the imaging arm.

#### Rheumatology key messages

- Chronic back pain ( $\leq 2$  years, onset  $< 45$  years) as referral symptom yields 40% of SpA patients.
- Sensitivity and specificity of the ASAS axSpA criteria are better than those of the ESSG, Amor and mNY criteria.
- SpA patients fulfilling either the clinical or imaging arm of the ASAS axSpA criteria are remarkably similar.

**Disclosure statement:** F.v.G. has received consulting fees of less than €1000 from Abbvie (formerly Abbott) and Pfizer. All other authors have declared no conflicts of interest.

## Supplementary data

Supplementary data are available at *Rheumatology* Online.

## References

- 1 Khan MA. Update on spondyloarthropathies. *Ann Intern Med* 2002;136:896–907.
- 2 van der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. *Arthritis Rheum* 1984;27:361–8.
- 3 Rudwaleit M, Landewe R, van der Heijde D *et al.* The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part I): classification of paper patients by expert opinion including uncertainty appraisal. *Ann Rheum Dis* 2009;68:770–6.
- 4 Dougados M, Vanderlinden S, Juhlin R *et al.* The European Spondylarthropathy Study Group preliminary criteria for the classification of spondylarthropathy. *Arthritis Rheum* 1991;34:1218–27.
- 5 Amor B, Dougados M, Mijiyawa M. Classification criteria of spondyloarthropathies. *Rev Rhum Mal Osteoartic* 1990;57:85–9.
- 6 Rudwaleit M, van der Heijde D, Landewe R *et al.* The development of Assessment of SpondyloArthritis international Society classification criteria for axial spondyloarthritis (part II): validation and final selection. *Ann Rheum Dis* 2009;68:777–83.
- 7 Rudwaleit M, van der Heijde D, Landewe R *et al.* The Assessment of SpondyloArthritis international Society classification criteria for peripheral spondyloarthritis and for spondyloarthritis in general. *Ann Rheum Dis* 2011;70:25–31.
- 8 Rudwaleit M, Khan MA, Sieper J. The challenge of diagnosis and classification in early ankylosing spondylitis: do we need new criteria? *Arthritis Rheum* 2005;52:1000–8.
- 9 van Tubergen A, Weber U. Diagnosis and classification in spondyloarthritis: identifying a chameleon. *Nat Rev Rheumatol* 2012;8:253–61.
- 10 Braun J, Sieper J. Ankylosing spondylitis. *Lancet* 2007;369:1379–90.
- 11 Poddubnyy D, Vahldiek J, Spiller I *et al.* Evaluation of 2 screening strategies for early identification of patients with axial spondyloarthritis in primary care. *J Rheumatol* 2011;38:2452–60.
- 12 Braun A, Saracbası E, Grifka J *et al.* Identifying patients with axial spondyloarthritis in primary care: how useful are items indicative of inflammatory back pain? *Ann Rheum Dis* 2011;70:1782–7.
- 13 Rojas-Vargas M, Munoz-Gomariz E, Escudero A *et al.* First signs and symptoms of spondyloarthritis—data from an inception cohort with a disease course of two years or less (REGISPONER-Early). *Rheumatology* 2009;48:404–9.
- 14 Rudwaleit M, van der Heijde D, Khan MA *et al.* How to diagnose axial spondyloarthritis early. *Ann Rheum Dis* 2004;63:535–43.

- 15 Rudwaleit M. New approaches to diagnosis and classification of axial and peripheral spondyloarthritis. *Curr Opin Rheumatol* 2010;22:375–80.
- 16 Sieper J, van der Heijde D, Landewe R *et al*. New criteria for inflammatory back pain in patients with chronic back pain: a real patient exercise by experts from the Assessment of SpondyloArthritis international Society (ASAS). *Ann Rheum Dis* 2009;68:784–8.
- 17 Heuft-Dorenbosch L, Landewe R, Weijers R *et al*. Performance of various criteria sets in patients with inflammatory back pain of short duration; the Maastricht early spondyloarthritis clinic. *Ann Rheum Dis* 2007;66:92–8.
- 18 Dougados M, D'Agostino MA, Benessiano J *et al*. The DESIR cohort: a 10-year follow-up of early inflammatory back pain in France: study design and baseline characteristics of the 708 recruited patients. *Joint Bone Spine* 2011;78:598–603.
- 19 Heuft-Dorenbosch L, Spoorenberg A, van Tubergen A *et al*. Assessment of enthesitis in ankylosing spondylitis. *Ann Rheum Dis* 2003;62:127–32.
- 20 Sieper J, Rudwaleit M, Baraliakos X *et al*. The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. *Ann Rheum Dis* 2009;68(Suppl 2):ii1–44.
- 21 van der Heijde D, Landewe R, Feldtkeller E. Proposal of a linear definition of the Bath Ankylosing Spondylitis Metrology Index (BASMI) and comparison with the 2-step and 10-step definitions. *Ann Rheum Dis* 2008;67:489–93.
- 22 Garrett S, Jenkinson T, Kennedy LG *et al*. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. *J Rheumatol* 1994;21:2286–91.
- 23 Calin A, Garrett S, Whitelock H *et al*. A new approach to defining functional ability in ankylosing spondylitis: the development of the Bath Ankylosing Spondylitis Functional Index. *J Rheumatol* 1994;21:2281–5.
- 24 Dougados M, Simon P, Braun J *et al*. ASAS recommendations for collecting, analysing and reporting NSAID intake in clinical trials/epidemiological studies in axial spondyloarthritis. *Ann Rheum Dis* 2011;70:249–51.
- 25 Lukas C, Landewe R, Sieper J *et al*. Development of an ASAS-endorsed disease activity score (ASDAS) in patients with ankylosing spondylitis. *Ann Rheum Dis* 2009;68:18–24.
- 26 Rudwaleit M, Jurik AG, Hermann KG *et al*. Defining active sacroiliitis on magnetic resonance imaging (MRI) for classification of axial spondyloarthritis: a consensual approach by the ASAS/OMERACT MRI group. *Ann Rheum Dis* 2009;68:1520–7.
- 27 Maksymowych WP, Inman RD, Salonen D *et al*. Spondyloarthritis Research Consortium of Canada magnetic resonance imaging index for assessment of sacroiliac joint inflammation in ankylosing spondylitis. *Arthritis Rheum* 2005;53:703–9.
- 28 Picavet HS, Schouten JS. Musculoskeletal pain in the Netherlands: prevalences, consequences and risk groups, the DMC(3)-study. *Pain* 2003;102:167–78.
- 29 Deyo RA, Rainville J, Kent DL. What can the history and physical examination tell us about low back pain? *JAMA* 1992;268:760–5.
- 30 Feldtkeller E, Khan MA, van der Heijde D *et al*. Age at disease onset and diagnosis delay in HLA-B27 negative vs. positive patients with ankylosing spondylitis. *Rheumatol Int* 2003;23:61–6.
- 31 Cheung PP, Paternotte S, Burki V *et al*. Performance of the assessment in SpondyloArthritis international Society classification for axial and peripheral spondyloarthritis in an established clinical cohort: comparison with criteria sets of Amor and the European Spondylarthropathy Study Group. *J Rheumatol* 2012;39:816–21.
- 32 van den Berg R, de Hooge M, Rudwaleit M *et al*. ASAS modification of the Berlin algorithm for diagnosing axial spondyloarthritis: results from the SPondyloArthritis Caught Early (SPACE)-cohort and from the Assessment of SpondyloArthritis international Society (ASAS)-cohort. *Ann Rheum Dis* 2012, Advance Access published 8 November 2012, doi:10.1136/annrheumdis-2012-201884.
- 33 Sieper J, van der Heijde D, Dougados M *et al*. Comparable levels of disease activity between axial spondyloarthritis patients classified through the MRI or HLA-B27 pathway of the ASAS criteria. *Ann Rheum Dis* 2011;70(Suppl 3):332.